You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy
|
|---|---|
| Published in |
Journal of Hematology & Oncology, October 2012
|
| DOI | 10.1186/1756-8722-5-63 |
| Pubmed ID | |
| Authors |
Weijing Sun |
| Abstract |
The diverse pathways and molecules involved in angiogenesis, the formation of new blood vessels, have been targeted for the treatment of colorectal and other cancers. Vascular endothelial growth factor (VEGF)-A binding to VEGF receptor (VEGFR)-2 is believed to be the key signaling pathway mediating angiogenesis. Other VEGF pathways involved in angiogenesis include VEGF-A, VEGF-B, and placental growth factor binding to VEGFR-1, and VEGF-C and VEGF-D binding to VEGFR-2 and VEGFR-3. VEGF signaling also intersects with other pathways, including angiopoietin/Tie, Notch, hypoxia-inducible factor, and integrin pathways. The roles of these pathways in tumor angiogenesis and in various human cancers will be explored in this article. In addition, preclinical and clinical data on bevacizumab, aflibercept (known as ziv-aflibercept in the US), and investigational antiangiogenic agents in development for the treatment of colorectal and other cancers will be reviewed. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 121 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Ecuador | 2 | 2% |
| Turkey | 1 | <1% |
| Brazil | 1 | <1% |
| Sweden | 1 | <1% |
| South Africa | 1 | <1% |
| Spain | 1 | <1% |
| Unknown | 114 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 22 | 18% |
| Student > Bachelor | 17 | 14% |
| Researcher | 15 | 12% |
| Student > Doctoral Student | 14 | 12% |
| Student > Master | 13 | 11% |
| Other | 18 | 15% |
| Unknown | 22 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 40 | 33% |
| Biochemistry, Genetics and Molecular Biology | 18 | 15% |
| Agricultural and Biological Sciences | 17 | 14% |
| Pharmacology, Toxicology and Pharmaceutical Science | 10 | 8% |
| Engineering | 4 | 3% |
| Other | 9 | 7% |
| Unknown | 23 | 19% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 October 2012.
All research outputs
#20,169,675
of 22,681,577 outputs
Outputs from Journal of Hematology & Oncology
#1,032
of 1,187 outputs
Outputs of similar age
#153,431
of 172,686 outputs
Outputs of similar age from Journal of Hematology & Oncology
#10
of 10 outputs
Altmetric has tracked 22,681,577 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,187 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.4. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 172,686 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one.